Microfluidic CTC Capture Using Multi-Biomarker Panels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CTC detection technologies face challenges in specificity and efficiency due to the heterogeneous expression of EPCAM biomarkers and the epithelial-mesenchymal transition of cancer cells, leading to missed detections and low capture rates of circulating tumor cells.
Innovation Solution
Identification of novel surface biomarkers (CD9, CD41, THBS1, RGS18, RGS10) through single-cell sequencing and bioinformatics analysis, combined with EPCAM, to enhance CTC capture and enrichment using a biomarker panel and microfluidic devices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If EPCAM-based immunoenrichment is used for CTC capture, then CTC enrichment efficiency is improved, but detection completeness deteriorates due to heterogeneous EPCAM expression and EMT
Solution Approach 1:
The patent segments the single EPCAM biomarker into multiple biomarkers (EPCAM, CD47, CD63, CD9, CD166, CD144, THBS1) and uses parallel immunoenrichment channels with different antibody combinations. This segmentation allows capturing CTCs with heterogeneous EPCAM expression levels and those undergoing EMT, thereby improving detection completeness while maintaining enrichment efficiency.
Solution Approach 2:
The patent creates a composite detection system combining multiple antibodies targeting different biomarkers (EPCAM/CD47/CD63/CD9/CD166/CD144/THBS1) on microbeads. This composite approach enables simultaneous recognition of diverse CTC phenotypes, resolving the contradiction between enrichment efficiency and detection completeness.
2Device complexity
If single biomarker (EPCAM) immunoenrichment is used, then device complexity is reduced, but measurement precision deteriorates due to missed detections
Solution Approach 1:
The patent divides the detection system into multiple independent channels, each targeting specific biomarker combinations. This segmentation allows precise detection of different CTC subpopulations without requiring a single complex multi-target system, thereby maintaining device simplicity while improving measurement precision.
Solution Approach 2:
The patent designs microbeads with universal structures that can be functionalized with different antibody combinations. This multi-functional design allows the same basic device architecture to detect multiple biomarkers, improving detection accuracy without proportionally increasing device complexity.
3Productivity
If microfluidic techniques are used for CTC isolation, then enrichment efficiency is improved, but specificity deteriorates due to reliance on cell size differences
Solution Approach 1:
The patent introduces antibody-coated microbeads as intermediaries between the microfluidic system and CTCs. These microbeads specifically bind to CTC surface biomarkers, adding immunological specificity to the physical microfluidic enrichment process. This intermediary approach maintains high enrichment efficiency while dramatically improving isolation specificity.
Solution Approach 2:
The patent merges microfluidic physical enrichment with immunological specific binding in an integrated system. The microfluidic channel provides efficient cell concentration based on size differences, while the antibody microbeads provide specific CTC identification and capture, together resolving the contradiction between enrichment efficiency and isolation specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly improves the capture and enrichment efficiency of CTCs in pancreatic and breast cancer patients, reducing missed detections and supporting personalized treatment strategies.
Implementation Method 1
Immunoassay for CTC detection mainly relies on the high-affinity binding between specific biomarkers on the surface of tumor cells and antibodies
Data Source
AI summary
The present disclosure belongs to the field of tumor diagnosis, and specifically relates to a biomarker panel, a microfluidic device and a detection kit for capturing circulating tumor cells. The biomarker panel includes a first biomarker and a second biomarker; wherein: the first biomarker is EPCAM; the second biomarker is one or a combination of two or more of CD9, CD41, THBS1, RGS18, and RGS10; the circulating tumor cells are pancreatic cancer circulating tumor cells and/or breast cancer circulating tumor cells. In the present disclosure, by using antibodies against novel surface biomarkers of pancreatic cancer or breast cancer circulating tumor cells (CTCs), the enrichment and detection rate of CTCs in the blood of patients are significantly improved, and the possibility of missed detection is effectively reduced; meanwhile, the capture and enrichment efficiency of CTCs are enhanced, thus providing strong support for dynamic tumor monitoring, prognostic evaluation and personalized precise treatment of cancer patients, and offering broad market value and application prospects.